| Literature DB >> 28642340 |
Mathieu Gayda1,2,3, Gabriel Lapierre4,2,5, Olivier Dupuy6, Sarah Fraser7, Louis Bherer4,2,3, Martin Juneau4,2,3, Vincent Gremeaux8, Anil Nigam4,2,3.
Abstract
The aim of this study was to compare cardiovascular hemodynamics and cerebral oxygenation/perfusion (COP) during and after maximal incremental exercise in obese individuals according to their aerobic fitness versus age-matched healthy controls (AMHC). Fifty-four middle-aged obese (OB) and 16 AMHC were recruited. Maximal cardiopulmonary function (gas exchange analysis), cardiac hemodynamics (impedance cardiography), and left frontal COP (near-infrared spectroscopy: NIRS) were measured continuously during a maximal incremental ergocycle test. During recovery, reoxygenation/perfusion rate (ROPR: oxyhemoglobin: ΔO2Hb, deoxyhemoglobin: ΔHHb and total hemoglobin: ΔtHb; with NIRS) was also measured. Obese participants (OB, n = 54) were divided into two groups according to the median V˙O2 peak: the low-fit obese (LF-OB, n = 27) and the high-fit obese (HF-OB, n = 27). During exercise, end tidal pressure of CO2 (PETCO2), and COP (ΔO2Hb, ΔHHb and ΔtHb) did not differ between groups (OB, LF-OB, HF-OB, AMHC). During recovery, PETCO2 and ROPR (ΔO2Hb, ΔHHb and ΔtHb) were similar between the groups (OB, LF-OB, HF-OB, AMHC). During exercise and recovery, cardiac index was lower (P < 0.05) in LF-OB versus the other two groups (HF-OB, AMHC). As well, systolic blood pressure was higher during exercise in the OB, LF-OB and HF-OB groups versus AMHC (P < 0.05). When compared to AMHC, obese individuals (OB, LF-OB, HF-OB) have a similar cerebral vasoreactivity by CO2 and cerebral hemodynamics during exercise and recovery, but a higher systolic blood pressure during exercise. Higher fitness in obese subjects (HF-OB) seems to preserve their cardiopulmonary and cardiac function during exercise and recovery.Entities:
Keywords: Cardiac and cerebral hemodynamics; exercise; obesity; recovery
Mesh:
Substances:
Year: 2017 PMID: 28642340 PMCID: PMC5492208 DOI: 10.14814/phy2.13321
Source DB: PubMed Journal: Physiol Rep ISSN: 2051-817X
Baseline clinical characteristics of aged‐matched healthy controls (AMHC), obese subjects (OB), obese low‐fit (OB‐LF) and obese high‐fit (OB‐HF) groups
| AMHC ( | OB ( | OB‐LF ( | OB‐HF ( | |
|---|---|---|---|---|
| Age (years) | 64 ± 4 | 62 ± 6 | 62 ± 7 | 61 ± 6 |
| Height (cm) | 172 ± 8 | 170 ± 9 | 169 ± 8 | 171 ± 10 |
| Female sex | 2 (33%) | 16 (29%) | 10 (37%) | 6 (26%) |
| Smoking | 0 (0%) | 4 (7%) | 2 (7%) | 2 (7%) |
| Hypertension | 0 (0%) | 29 (53%) | 15 (55%) | 14 (51%) |
| Diabetes | 0 (0%) | 22 (40%) | 16 (59%) | 6 (22%) |
| History of dyslipidemia | 0 (0%) | 27 (50%) | 17 (62%) | 10 (18%) |
| Obesity | 0 (0%) | 54 (100%) | 27 (100%) | 27 (100%) |
| Medication | ||||
| Beta–blockers | 0 (0%) | 8 (14%) | 5 (18%) | 3 (11%) |
| ACE inhibitors | 0 (0%) | 14 (25%) | 7 (25%) | 7 (25%) |
| Antiplatelet agents | 0 (0%) | 7 (12%) | 5 (18%) | 2 (7%) |
| Angiotensin receptor blockers | 0 (0%) | 16 (29%) | 9 (33%) | 7 (25%) |
| Statin | 0 (0%) | 24 (44%) | 14 (51%) | 10 (37%) |
| Calcium channel blockers | 0 (0%) | 6 (11%) | 5 (18%) | 1 (3%) |
| Hypoglycemic agents | 0 (0%) | 8 (14%) | 8 (27%) | 0 (0%) |
| Body composition | ||||
| Body mass (kg) | 73 ± 8 | 93 ± 17 | 94 ± 17 | 91 ± 17 |
| BMI (kg/m2) | 24.5 ± 2.0 | 31.9 ± 5.0 | 32.9 ± 4.9 | 31.0 ± 5.0 |
| Waist circumference (cm) | 90 ± 7 | 110 ± 13 | 113 ± 13 | 107 ± 12 |
| Lean body mass (kg) | 57.8 ± 8.0 | 61.0 ± 11.9 | 60.1 ± 12.0 | 61.9 ± 11.9 |
| FM percentage (%) | 20.9 ± 4.2 | 34.1 ± 6.9 | 36.2 ± 6.2 | 32.2 ± 7.0 |
| Total FM (kg) | 15.2 ± 2.7 | 31.9 ± 9.6 | 34.3 ± 8.9 | 29.6 ± 9.9 |
| Trunk FM percentage (%) | 21.4 ± 3.7 | 34.9 ± 5.5 | 36.6 ± 4.9 | 33.2 ± 5.7 |
| Trunk FM (kg) | 8.9 ± 1.8 | 17.9 ± 5.6 | 19.1 ± 4.7 | 16.8 ± 6.3 |
| Blood analysis | ||||
| Fasting glucose (mmol/L) | 4.9 ± 0.3 | 6.1 ± 1.4 | 6.6 ± 1.6 | 5.7 ± 1.0 |
| Total cholesterol (mmol/L) | 4.92 ± 0.87 | 4.51 ± 1.61 | 4.33 ± 1.09 | 4.67 ± 1.96 |
| HDL–cholesterol (mmol/L) | 1.54 ± 0.42 | 1.24 ± 0.34 | 1.22 ± 0.38 | 1.25 ± 0.31 |
| LDL–cholesterol (mmol/L) | 3.13 ± 0.63 | 2.44 ± 0.77 | 2.44 ± 0.66 | 2.44 ± 0.90 |
| Triglycerides (mmol/L) | 0.73 ± 0.19 | 1.50 ± 0.90 | 1.58 ± 0.88 | 1.43 ± 0.93 |
| Triglycerides/HDL | 0.52 ± 0.25 | 1.35 ± 1.08 | 1.48 ± 1.1 | 1.25 ± 0.99 |
ACE, angiotensin–converting enzyme; CABG, coronary artery bypass grafting surgery; CHD, coronary heart disease; MI, myocardial infarction; PCI, percutaneous coronary intervention; BMI, body mass index; FM, fat mass; SBP, systolic blood pressure; DBP, diastolic blood pressure.
Group effect: aAMHC versus OB, bAMHC versus OB‐LF, cAMHC versus OB‐HF, dOB‐LF versus OB‐HF.
1Rest SBP > 130 mmHg; 2glucose > 7 mmol/l; 3Body fat mass %: women > 35% and men > 25%.
*P < 0.05, † P < 0.01, ‡ P < 0.001, § P < 0.0001.
Cardiopulmonary and hemodynamic variables at rest and during exercise testing in aged‐matched healthy controls (AMHC), obese subjects (OB), obese low‐fit (OB‐LF) and obese high‐fit (OB‐HF) groups
| Cardiopulmonary and hemodynamic variables | AMHC ( | OB ( | OB‐LF ( | OB‐HF ( | ANOVA | |
|---|---|---|---|---|---|---|
| AMHC vs. OB | AMHC vs. OB‐LF vs. OB‐HF | |||||
| Rest | ||||||
| Resting heart rate | 63 ± 7 | 77 ± 14 | 76 ± 15 | 77 ± 13 | 0.0006 | 0.0031 |
| Rest SBP (mmHg) | 119 ± 15 | 130 ± 11 | 130 ± 13 | 129 ± 9 | 0.0023 | 0.0089 |
| Rest DBP (mmHg) | 73 ± 10 | 75 ± 12 | 74 ± 16 | 75 ± 8 | 0.6203 | 0.8312 |
| At ventilatory threshold | ||||||
|
| 33.3 ± 5.2 | 27.4 ± 5.7 | 22.9 ± 3.6 | 31.4 ± 4.0 | <0.0001 | 0.0009 |
| Power (Watts) | 148 ± 43 | 110 ± 43 | 83 ± 28 | 135 ± 39 | 0.0050 | <0.0001 |
| At peak | ||||||
|
| 44.5 ± 6.0 | 37.3 ± 7.7 | 30.9 ± 4.4 | 43.6 ± 4.3 | 0.0011 | <0.0001 |
| % of | 139 ± 16 | 110 ± 35 | 98 ± 21 | 122 ± 42 | 0.0049 | <0.0001 |
|
| 2918 ± 719 | 2613 ± 817 | 2091 ± 593 | 3096 ± 693 | 0.2079 | <0.0001 |
| R.E.R | 1.15 ± 0.06 | 1.14 ± 0.07 | 1.15 ± 0.07 | 1.13 ± 0.08 | 0.6064 | 0.4706 |
| Peak power (Watts) | 204 ± 47 | 162 ± 60 | 122 ± 35 | 198 ± 55 | 0.0131 | <0.0001 |
|
| 94 ± 30 | 82 ± 26 | 66 ± 20 | 96 ± 23 | 0.1406 | <0.0001 |
| % of | 139 ± 35 | 126 ± 36 | 105 ± 29 | 145 ± 31 | 0.2263 | <0.0001 |
|
| 32 ± 6 | 31 ± 4 | 31 ± 4 | 32 ± 5 | 0.6754 | 0.8180 |
| TV (liters) | 2.58 ± 0.45 | 2.25 ± 0.58 | 2.04 ± 0.51 | 2.45 ± 0.58 | 0.0549 | 0.0040 |
| Bf (resp/min) | 37 ± 11 | 36 ± 8 | 33 ± 8 | 40 ± 8 | 0.9798 | 0.0272 |
| CO (L/min) | 15.5 ± 3.4 | 15.0 ± 3.4 | 14.0 ± 3.6 | 15.9 ± 2.9 | 0.5871 | 0.1082 |
| CI max (L/min/m2) | 7.9 ± 1.7 | 7.3 ± 1.7 | 6.8 ± 1.8 | 7.8 ± 1.6 | 0.2220 | 0.0513 |
| C(a‐v)O2 (mL/100 mL) | 15.1 ± 3.1 | 16.0 ± 3.5 | 15.9 ± 3.1 | 16.1 ± 4.0 | 0.6216 | 0.6618 |
| SVi (mL/m2) | 54 ± 6 | 53 ± 11 | 51 ± 14 | 55 ± 8 | 0.6524 | 0.2433 |
| EDVi (mL/m2) | 119 ± 31 | 129 ± 71 | 121 ± 33 | 136 ± 96 | 0.6216 | 0.6296 |
| ESVi (mL/m2) | 64 ± 32 | 66 ± 34 | 67 ± 35 | 66 ± 33 | 0.8378 | 0.9591 |
| LCWi (kg.m/m²) | 11.8 ± 3.1 | 11.4 ± 3.2 | 10.6 ± 3.1 | 12.2 ± 3.1 | 0.6842 | 0.1422 |
| SVRi (dyn.s/cm5.m²) | 616 ± 156 | 666 ± 198 | 719 ± 250 | 615 ± 113 | 0.3568 | 0.0819 |
| Peak HR (bpm) | 154 ± 10 | 147 ± 24 | 137 ± 25 | 158 ± 18 | 0.2819 | 0.0008 |
| ΔHRR at 1 min (bpm) | −20 ± 6 | −24 ± 14 | −20 ± 12 | −27 ± 14 | 0.3363 | 0.0482 |
| Max SBP (mmHg) | 186 ± 24 | 193 ± 27 | 196 ± 29 | 191 ± 26 | 0.3359 | 0.5050 |
| Max DBP (mmHg) | 81 ± 11 | 79 ± 14 | 76 ± 18 | 81 ± 7 | 0.5575 | 0.3585 |
SBP, systolic blood pressure; DBP, diastolic blood pressure; LBM, lean body mass; R.E.R, respiratory exchange ratio; TV, tidal volume; Bf, breathing frequency; CI, cardiac index; C(a‐v)O2, arterio venous difference; SVi, stroke volume index; LCWi, left cardiac work index; SVRi, systemic vascular resistance index; HR, heart rate; HRR, heart rate recovery.
Group effect: aAMHC versus OB, bAMHC versus OB‐LF, cAMHC versus OB‐HF, dOB‐LF versus OB‐HF.
*P < 0.05, † P < 0.01, ‡ P < 0.001, § P < 0.0001.
Correlation between peak, pulmonary and cardiovascular parameters (at peak) in aged‐matched healthy controls (AMHC) and obese subjects (OB).
|
|
| |
|---|---|---|
| At peak | AMHC | OB |
|
|
|
|
| VT |
|
|
| Bf |
|
|
| CO |
|
|
| CI |
|
|
| C(a‐v)O2 |
|
|
| SVi |
|
|
| EDVi |
|
|
| ESVi |
|
|
| LCWi |
|
|
| SBP |
|
|
| DBP |
|
|
Emax, maximal ventilation; TV, tidal volume; Bf, breathing frequency; CO, cardiac ouput; CI, cardiac index; C(a‐v)O2, arterio venous difference; SVi, stroke volume index; EDVi, end diastolic volume index; ESVi, end systolic volume index; LCWi, left cardiac work index; SBP, systolic blood pressure; DBP, diastolic blood pressure.
Figure 1PETCO 2, cardiac index, systolic and diastolic blood pressure during exercise in aged‐matched healthy controls (AMHC) and obese subjects (OB). ANOVA effect: A=group, B=time, C=interaction; Post hoc group effect: *= P < 0.05.
Figure 2PETCO 2, cardiac index, systolic and diastolic blood pressure during exercise in aged‐matched healthy controls (AMHC), low‐fit obese group (LF‐OB) and high‐fit obese group (HF‐OB). ANOVA effect: A=group, B=time, C=interaction; Post hoc group effect: a=AMHC versus LF‐OB, b=LF‐OB versus HF‐OB, c=AMHC versus HF‐OB, *= P < 0.05, &=P < 0.01, $=P < 0.001, #=P < 0.0001.
Figure 3PETCO 2, cardiac index, systolic and diastolic blood pressure during recovery in aged‐matched healthy controls (AMHC) and obese subjects (OB). ANOVA effect: A=group, B=time, C=interaction; Post hoc group effect: *=P < 0.05.
Figure 4PETCO 2, cardiac index, systolic and diastolic blood pressure during exercise in aged‐matched healthy controls (AMHC), low‐fit obese group (LF‐OB) and high‐fit obese group (HF‐OB). ANOVA effect: A=group, B=time, C=interaction; Post hoc group effect: b=LF‐OB vs. HF‐OB, c=AMHC vs HF‐OB, *=P < 0.05, &=P < 0.01, $=P < 0.001, #=P < 0.0001.
Figure 5Cerebral oxygenation/perfusion during exercise in age‐matched healthy controls (AMHC), obese subjects (OB), low‐fit obese group (LF‐OB) and high‐fit obese group (HF‐OB). ANOVA effect: A=group, B=time, C=interaction.
Figure 6Cerebral oxygenation/perfusion during recovery in age‐matched healthy controls (AMHC), obese subjects (OB), low‐fit obese group (LF‐OB) and high‐fit obese group (HF‐OB). ANOVA effect: A=group, B=time, C=interaction.